Skin autofluorescence measured advanced glycation end product, which was associated with impaired bone health among patients with type 1 diabetes.

Polypharmacy among patients with early RA was associated with lower rates of remission and an increased risk for SAEs over a 10-year period.

Data from 2 prospective cohort studies showed that chondrocalcinosis was significantly associated with increased odds of incident radiographic knee OA.

Use of a digital intervention led to clinically significant reductions in psychological distress at 3 months among patients with IRDs.

Complete, but not partial, remission was associated with a lower likelihood of doubling of serum creatinine in patients with pure membranous lupus nephritis.

Greater improvements in disability and pain intensity were seen at 6 and 12 months with acupuncture vs usual care among patients with CLBP.

Cumulative influenza-associated hospitalization rates during the 2024 to 2025 season were higher than all end-of-season rates from the 2010 to 2011 season onward.

Rates of alcohol-induced deaths in the United States increased by 89% from 1999 to 2024, most notably among women aged 25 to 34 years.

Tirzepatide and semaglutide had a 64% and 34% probability of being cost-effective at a $100,000 per QALY threshold, respectively.

Topline data were announced from a phase 3 trial evaluating garetosmab in adults with fibrodysplasia ossificans progressiva.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo for IV administration in the treatment of moderate to severe SLE.

Willingness to prescribe estrogen therapy for patients with a history of gynecologic cancer varied by specialty, experience, and sex.